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The intramembrane protease g-secretase is a key player in signaling and Alzheimer’s disease, but
its structural features have remained obscure. A structure reported recently reveals a horseshoe-
shaped arrangement of 19 transmembrane helices and an extracellular domain positioned for
substrate recognition. This advance bodes well for a finer resolution before long.When Galileo trained his telescope on
Jupiter, he only found 4 of the now 67
confirmed moons of the Giant Planet,
but his discovery represented a profound
leap in our understanding of the cosmos.
In an article in Nature, Lu et al. (2014)
now report the use of a new type of elec-
tron detector to determine the structure of
the g-secretase complex at about 4.5 A˚
resolution, too low for atomic detail but
nevertheless providing insights into the
apparent workings of this membrane-
embedded protease complex that is so
critical in biology and medicine.
The name g-secretase was first used to
describe a protease activity by which the
transmembrane domain (TMD) of the am-
yloid b-protein precursor (APP) is cleaved
to produce the amyloid b-protein (Ab) that
notoriously deposits in the brain in Alz-
heimer’s disease (AD). The discovery of
dominant mutations in the 9-TMD pro-
teins presenilin-1 and -2 (PS1 and PS2)
that cause rare forms of early-onset AD
(Sherrington et al., 1995) soon led to the
finding that presenilin is essential for
g-secretase activity (De Strooper et al.,1998) and is a founding member of a
new class of intramembrane-cleaving
protease (I-CLiPs) (Wolfe et al., 1999a).
With the discovery of two TMD aspartates
necessary for proteolytic activity (Wolfe
et al., 1999b), the presenilins were found
to recapitulate through convergent evolu-
tion the basic mechanism of soluble as-
partyl proteases. Other I-CLiPs include
the site 2 protease (S2P) family of metallo-
proteases and the rhomboid family of
serine proteases.
But g-secretase is much more than pre-
senilin. Threeothermembraneproteinsare
also essential subunits of the protease
complex: nicastrin, Aph1, and Pen2. The
four components assemble together in
the ER, whereupon presenilin is activated
to undergo autoproteolysis into an N-ter-
minal fragment (NTF) and a C-terminal
fragment (CTF),with theactivesite residing
at the interface between these two newly
formed subunits. Importantly, g-secretase
cleaves many other substrates besides
APP, most notably the Notch family of re-
ceptors, the cleavage of which is required
for signaling essential to all metazoans.Muchhasbeendone toelucidatehowg-
secretase accomplishes hydrolysis of
peptide bonds within the membrane, how
this enzyme can go awry in AD, and how
its function might be altered in a
therapeutically safe manner. Regarding
structure, several previous electronmicro-
scopy (EM) studies (oneusingcryo-EM) re-
vealedbasic dimensionsandorientation of
the complex, potential sites for water and
substrate entry, and conformational
changes that occur upon inhibitor binding.
But the relatively poor resolution (12 A˚ at
best) of these structures offered little func-
tional insight. In stark contrast, crystal
structures of rhomboid, S2P, and an
archaeal presenilin homolog provided
detailed snapshots of these other I-CLiPs.
All of these, however, work as single poly-
peptides, unlikeg-secretase,whosestruc-
ture is much more complex.
In solving a structure of g-secretase, Lu
and colleagues optimize expression and
purification of active complexes from a
human cell line and identify a suitable
detergent that is conducive to clearer
EM images. They also employ direct158, July 17, 2014 ª2014 Elsevier Inc. 247
Figure 1. General Architecture of the g-Secretase Complex and Implications for Substrate
Access and Recognition
(A) The new structure by Lu et al. reveals a horseshoe-shaped arrangement of transmembrane domains
(TMDs) and a bilobed nicastrin ectodomain (ECD). The nicastrin sequence and structure are homologous
to a peptidase but without catalytic activity of its own. Nicastrin’s catalytically dead site (star) is part of a
groove located above the opening to the horseshoe-shaped TMD arrangement and may be important for
substrate access and recognition (arrow represents the lateral approach of substrate).
(B) Speculated arrangement of specific TMDs of PS1 (numbered) and Pen-2 (P) in the thick end, based in
part on the structure of an archaeal presenilin homolog. TMDs of Aph-1 and nicastrin are nonspecifically
assigned to the thin end. Substrate (S) approaches the active site, located between TMD 6 and 7 of PS1,
via the cavity.electron detection for cryo-EM data
collection along with newmethods for sin-
gle-particle image analysis and 3D recon-
struction that allow faster acquisition
times and require fewer particles (Bai
et al., 2013), methods that have recently
revolutionized structure determination of
large protein complexes using EM.
The results are eye opening, revealing
previously unseen features of the prote-
ase complex. The overall model includes
a horseshoe-shaped arrangement of the
19 TMDs and a bilobed ectodomain
(ECD) representing nicastrin (Figure 1A).
Although nearly half of the mass of the
complex was disordered and therefore
unaccounted for, much of this included
glycosylation on nicastrin and uncon-
served cytosolic parts of PS1. However,
also missing from the structure are loop
regions and the C terminus of PS1 that
are known to be important for protease
function. Some of these absent parts
may be disordered because their confor-
mational flexibility is crucial to substrate
binding and proteolytic processing or for
enzyme regulation. Of note, the general
structure supports only one of each of
the four g-components being present in
an active complex (Sato et al., 2007).
The clearest part of this new structure is
the nicastrin extracellular domain, with an
average resolution of 3.5 A˚. Intriguingly,
the authors point out that this domain is248 Cell 158, July 17, 2014 ª2014 Elsevier Inhomologous both in sequence and in
structure to the glutamate carboxyl pep-
tidase PSMA (prostate-specific mem-
brane antigen). Although most of the
PSMA zinc-binding residues required for
its peptidase activity are replaced in ni-
castrin, this subunit of g-secretase may
be involved in substrate binding, as pre-
viously suggested (Shah et al., 2005).
The hypothesized site for substrate inter-
action (star in Figure 1A) is tantalizingly
located at a reasonable distance above
the membrane and also above the open
portion of the horseshoe of TMDs that
could be the site for lateral access of the
substrate TMD into the protease. Func-
tional evidence will be required to support
these speculations on the substrate
recognition site, but the new structure
provides a much better framework for
designing such experiments.
The specific assignment of each of the
19 TMDs of g-secretase to the 19 helices
in the horseshoe structure remains ambig-
uous due to the relatively low resolution of
this region. The authors observe that the
density of the TMDs is such that one end
of the horseshoe is thicker (three layers
of TMDs) than the other (two layers)
(Figure 1B). The thick end is consistent
with the structure of an archaeal presenilin
homolog that this laboratory solved previ-
ously (Li et al., 2013a). This, along with a
clear connection between four contiguousc.TMDs, suggests a likely assignment for
the nine TMDs of PS1 catalytic compo-
nent within the thick end. This leaves the
two-TMD Pen-2 component interacting
with TMD4 of PS1, consistent with previ-
ous biochemical studies, but also nestling
intimately with PS1 TMDs 7 and 8, sug-
gesting how this small subunit might
induce conformational changes in PS1
that lead to its autoproteolysis. The thin
end of the horseshoe was therefore as-
signed to the TMDs of Aph1 and nicastrin,
but their specific distribution is unclear.
The role of the seven-TMD Aph1 remains
mysterious, though it has been suggested
as a scaffolding protein for the rest of the
g-complex and may also be involved in
substrate recognition (Chen et al., 2010).
Although g-secretase has come into
clearer focus with this study, much still
remains to be done.Obviously, higher res-
olution is needed, but the conformational
flexibility of the complex could be a hin-
drance. Stabilization with peptidomimetic
inhibitors may help in this regard and may
provide further insight into substrate inter-
action and handling. Imaging and recon-
structions of different conformations,
taken under different biochemical condi-
tions, could give a sense of protein dy-
namics and enzyme regulation. Further in-
sights into the roles of the subunits
supporting presenilin’s proteolytic func-
tions should be gained in the process. Ul-
timately, higher resolution of different
conformational states of g-secretase and
bound to different inhibitors and modula-
tors could allow structure-based design
of safer, more effective compounds for
treating AD, for which several potentially
disease-modifying therapies are in human
trials. The new structure is amajor step to-
ward this great goal.
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